Several other predictors, including tumor mutational burden, gut microbial diversity, and mutations in the b-catenin or STK11 gene, have been reported as candidate biomarkers that complement the predictive role of PD-L1, but those biomarkers require further validation [3]. The gene discussed is CD274; the disease is neoplasm.